BOD approve 2021Q4 consolidated financial statements
· Issued by Amcad Biomed Corporation
Close
Today's Information
Provided by: AmCad BioMed Corporation
SEQ_NO
1
Date of announcement
2022/02/18
Time of announcement
15:31:55
Subject
AmCad BOD approve 2021Q4 consolidated
financial statements
Date of events
2022/02/18
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/02/18
2.Date of the audit committee approved:2022/02/18
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2021/01/01~2021/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):85,791
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):60,665
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(36,771)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(26,890)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(26,890)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(25,544)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(0.48)
11.Total assets end of the period (thousand NTD):615,752
12.Total liabilities end of the period
(thousand NTD):36,722
13.Equity attributable to owners of parent end of the
period (thousand NTD):482,975
14.Any other matters that need to be specified:None
